Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lineage Therap ( (LCTX) ) has issued an announcement.
Lineage Cell Therapeutics announced a multi-year research collaboration with William Demant Invest 2 Aps to advance its auditory neuronal cell transplant program, ReSonance, aimed at treating hearing loss. The agreement, established on August 22, 2025, involves WDI funding up to $12 million over three years to achieve preclinical readiness for potential human clinical trials, with both parties sharing joint ownership of project results.
The most recent analyst rating on (LCTX) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Lineage Therap stock, see the LCTX Stock Forecast page.
Spark’s Take on LCTX Stock
According to Spark, TipRanks’ AI Analyst, LCTX is a Neutral.
Lineage Therap’s stock score is primarily impacted by its financial performance challenges, including ongoing losses and weak cash flow. The technical analysis shows bullish momentum, which is a positive factor, but the valuation remains unattractive due to a negative P/E ratio. The earnings call provided some optimism with clinical advancements and a strong cash position, but financial losses and operational uncertainties remain significant concerns.
To see Spark’s full report on LCTX stock, click here.
More about Lineage Therap
Lineage Cell Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of cell therapies. The company is known for its innovative approaches in regenerative medicine, particularly in creating therapies for degenerative diseases.
Average Trading Volume: 2,477,497
Technical Sentiment Signal: Buy
Current Market Cap: $267.2M
See more data about LCTX stock on TipRanks’ Stock Analysis page.